https://www.selleckchem.com/pr....oducts/miransertib.h
HER2 kinase as a well-established target for breast cancer (BC) therapy is associated with aggressive clinical outcomes; thus, herein we present structural optimization for HER2-selective targeting. HER2 profiling of the developed derivatives demonstrated potent and selective inhibitions (IC50 5.4-12 nM) compared to lapatinib (IC50 95.5 nM). Favorably, 17d exhibited minimum off-target kinase activation. NCI-5-dose screening revealed broad-spectrum activities (GI50 1.43-2.09 μM) and 17d had a remarkable selectivity toward BC. Our com